Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows

Source: Immuno-Oncology News, July 2017

It took longer for advanced melanoma to recur in patients treated with Bristol-Myers Squibb’s Opdivo (nivolumab) than in patients who received Yervoy, according to a Phase 3 clinical trial.

The findings applied to patients with stage 3b/c or stage 4 melanoma at high risk of recurrence after surgery. A company news release did not specify how much longer it took for the Opvido patients’ cancer to recur than the Yervoy patients.

Researchers are using the CheckMate 238 trial (NCT02388906) to compare the effectiveness of Opdivo and Yervoy (ipilimumab), which is also a Bristol-Meyers drug, as treatments for advanced melanoma. The U.S. Food and Drug Administration has already approved both therapies.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories